Cystic fibrosis

Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing

Retrieved on: 
Tuesday, January 30, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Urinary tract infection, Chronic obstructive pulmonary disease, CFTR, Mortality, FEV1, Respiratory disease, Therapy, Disease, Patient, Enterprise, Mucus, IP Group, Cystic fibrosis, Epithelial sodium channel, Asthma, Atomic mass

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.

Key Points: 
  • Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.
  • Existing investors Versant Ventures, Novartis Venture Fund, Forbion, Epidarex Capital and IP Group also participated.
  • Alongside the financing, Dr Rob Woodman, Partner at Panakes, joins Enterprise’s Board of Directors.
  • Dr John Ford, CEO, Enterprise Therapeutics, said: “We have made tremendous progress to date in developing novel therapeutics for patients suffering from chronic respiratory diseases.

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Retrieved on: 
Thursday, January 25, 2024
Cystic fibrosis, Patient, Pancreas, Research, Cystic Fibrosis Foundation, Urinary tract infection, CFTR, DSM-IV codes, Nonsense, Mutation, Disease, Mucus, Vaccine

Funding from the CF Foundation will allow Prime Medicine to progress two distinct strategies for applying Prime Editing to treat CF: hotspot editing and PASSIGE™ (Prime Assisted Site Specific Integrase Gene Editing).

Key Points: 
  • Funding from the CF Foundation will allow Prime Medicine to progress two distinct strategies for applying Prime Editing to treat CF: hotspot editing and PASSIGE™ (Prime Assisted Site Specific Integrase Gene Editing).
  • Through hotspot editing, the Company aims to address multiple mutations at mutational hotspots with a small number of Prime Editors.
  • Prime Medicine has begun preclinical research to use hotspot Prime Editors to correct the G542X nonsense CFTR mutation, and plans to extend this work to develop hotspot Prime Editors for other clusters of CFTR mutations.
  • Prime Medicine is eligible for an additional $6 million upon achieving certain preclinical milestones, with up to $3 million in supplementary funding upon mutual agreement.

4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease

Retrieved on: 
Tuesday, January 23, 2024
Cystic fibrosis, CFTR, Food, Disease, FDA, Marketing, Clinical trial, Pharmaceutical industry

4D-710 is being evaluated in the Phase 1/2 AEROW clinical trial in people with CF who are not eligible for, or cannot tolerate any of, the currently approved CFTR modulators.

Key Points: 
  • 4D-710 is being evaluated in the Phase 1/2 AEROW clinical trial in people with CF who are not eligible for, or cannot tolerate any of, the currently approved CFTR modulators.
  • RPDD may be granted to investigational drugs and biologics designed to address serious or life-threatening diseases primarily affecting individuals 18 years of age and under, and meeting the definition of “rare disease or condition” (affects less than 200,000 individuals in the U.S.).
  • If the drug or biologic is approved for marketing, 4DMT may qualify for a priority review voucher that may be transferred or sold to another sponsor.
  • “Based on the CFTR expression levels and clinical activity seen to-date, we are excited about the potential for 4D-710 to transform the lives of people with CF with an effective and durable treatment option.

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Retrieved on: 
Thursday, January 25, 2024
Biotechnology, Health, Philanthropy, General Health, Health Technology, Other Science, Research, Fund Raising, Genetics, Foundation, Science, Cystic fibrosis, MD, Cystic Fibrosis Foundation, DNA, CFTR, Mutation, Sickle cell disease, Gene, Gene editing, FDA, Pharmaceutical industry

Today, the Cystic Fibrosis Foundation announced that it will provide up to $15 million to Prime Medicine for preclinical research into gene editing for cystic fibrosis.

Key Points: 
  • Today, the Cystic Fibrosis Foundation announced that it will provide up to $15 million to Prime Medicine for preclinical research into gene editing for cystic fibrosis.
  • Prime Medicine is using a gene editing technology called prime editing — a technology that enables insertions or deletions of small segments of DNA at precise sites.
  • Prime Medicine — founded by researchers who pioneered the development of this unique editing technology — is investigating whether prime editing could treat several diseases, including CF.
  • Prime Medicine intends to use prime editing to fix the CFTR gene by inserting a part of the DNA that codes for the CFTR gene.

AllerVie Health Expands Technology Infrastructure to Prioritize Innovation and Patient Experience

Retrieved on: 
Tuesday, January 23, 2024
Software, Practice Management, General Health, Health, Medical Devices, Health Technology, Technology, Apps, Applications, Cystic fibrosis, Patient, Chronic obstructive pulmonary disease, EMR, Asthma, Allergy, Communication, COPD, DLCO, Spirometry, Growth

"We are excited about our technology transformations this year and how they are enabling us to advance patient care and outcomes," said Chris Roussos, CEO of AllerVie Health.

Key Points: 
  • "We are excited about our technology transformations this year and how they are enabling us to advance patient care and outcomes," said Chris Roussos, CEO of AllerVie Health.
  • Key highlights of digital advancements include:
    In 2023, AllerVie Health expanded its deployment of a state-of-the-art pulmonary function testing solution to 30 clinics nationwide.
  • AllerVie Health implemented a new electronic medical record (EMR) system in 14 clinics across Florida and Georgia during 2023.
  • AllerVie Health's collaboration with a prominent digital health company specializing in respiratory health management broadens the utilization of a portable digital respiratory health tool and app across a more extensive range of clinics within the AllerVie Health network.

Global Pseudomonas Aeruginosa Infection Treatment Market Report 2023 and 2024-2030: North America and Asia Pacific Earmarked for Exceptional Growth Trajectories - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 16, 2024
Biotechnology, Pharmaceutical, Health, Cystic fibrosis, Pseudomonas aeruginosa, Infection, Research, Carbapenem, Novartis, Cancer, Gilead Sciences, Acquisition, USD, Prevalence, Pharmaceutical industry

The "Global Pseudomonas Aeruginosa Infection Treatment Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pseudomonas Aeruginosa Infection Treatment Market" report has been added to ResearchAndMarkets.com's offering.
  • The report uncloaks nuanced market trajectories and dynamics, providing insights into the promising developments toward antibiotic resistance.
  • Predicted to rise rapidly, the Asia Pacific market's growth orbit is propelled by heightened healthcare awareness and escalating healthcare investments.
  • North America and Asia Pacific regions earmarked for exceptional growth trajectories.

Global Ultrasonic Nebulizer Market to Reach US$ 325.6 Million by 2030, Rising at a CAGR of 5.9% | Report by CoherentMI

Retrieved on: 
Tuesday, January 16, 2024
Cystic fibrosis, World Health Organization, Patient, Chronic obstructive pulmonary disease, Research, Incidence, Hospital, Inhalation, Agilent Technologies, U22, Ultrasound, Asthma, Administration, Growth, Quality of life, Respiratory system, WHO, Health, Omron, Particle size, Prevalence, Pharmaceutical industry

Among the end users, hospitals and clinics are expected to dominate the global ultrasonic nebulizer market.

Key Points: 
  • Among the end users, hospitals and clinics are expected to dominate the global ultrasonic nebulizer market.
  • Key players operating in the global ultrasonic nebulizer market include Philips Healthcare, Omron, PARI Medical, BD, and Agilent Technologies, among others.
  • Large-volume ultrasonic nebulizers are expected to dominate the global ultrasonic nebulizer market in terms of product type.
  • Overall, the global ultrasonic nebulizer market offers lucrative opportunities in large-volume nebulizers for COPD treatment and the growing demand for home healthcare solutions.

Global Ultrasonic Nebulizer Market to Reach US$ 325.6 Million by 2030, Rising at a CAGR of 5.9% | Report by CoherentMI

Retrieved on: 
Tuesday, January 16, 2024
Cystic fibrosis, World Health Organization, Patient, Chronic obstructive pulmonary disease, Research, Incidence, Hospital, Inhalation, Agilent Technologies, U22, Ultrasound, Asthma, Administration, Growth, Quality of life, Respiratory system, WHO, Health, Omron, Particle size, Prevalence, Pharmaceutical industry

Among the end users, hospitals and clinics are expected to dominate the global ultrasonic nebulizer market.

Key Points: 
  • Among the end users, hospitals and clinics are expected to dominate the global ultrasonic nebulizer market.
  • Key players operating in the global ultrasonic nebulizer market include Philips Healthcare, Omron, PARI Medical, BD, and Agilent Technologies, among others.
  • Large-volume ultrasonic nebulizers are expected to dominate the global ultrasonic nebulizer market in terms of product type.
  • Overall, the global ultrasonic nebulizer market offers lucrative opportunities in large-volume nebulizers for COPD treatment and the growing demand for home healthcare solutions.

VIVUS Provides Update on Pipeline and Program Milestones

Retrieved on: 
Monday, January 8, 2024
Patient, Quality of life, HIV/AIDS, Bloating, Diarrhea, Inflammatory bowel disease, ABPM, Chronic pain, Enzyme replacement therapy, Cystic fibrosis, Heart, Degenerative disease, Exocrine pancreatic insufficiency, Comorbidity, Steatorrhea, Obesity, HIV, Amylase, Orthostatic hypertension, Phentermine, Heart failure, Exercise, Pharmaceutical industry

CAMPBELL, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced pipeline updates and program milestones.

Key Points: 
  • CAMPBELL, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced pipeline updates and program milestones.
  • “VIVUS has been continuously dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases, including exocrine pancreatic insufficiency, obesity and pulmonary arterial hypertension,” said John Amos, Chief Executive Officer at VIVUS LLC.
  • QSYMIA® is now the number one branded oral product in the US for obesity treatment.
  • Moreover, VIVUS is actively developing pipeline products focusing on bone marrow transplant preparation (VI-0609) and diabetes treatments (VI-0809 and VI-0810).”

Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva

Retrieved on: 
Monday, January 8, 2024
Acquisition, Cystic fibrosis, Pseudomonas aeruginosa, Mucus, Infection, Patient, Bacteria, Medicine, Psoriatic arthritis, Pharmaceutical industry

Zug, Switzerland and Egham, UK – 8 January 2024 – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of European rights to Colobreathe® from Teva Laboratories UK Limited.

Key Points: 
  • Zug, Switzerland and Egham, UK – 8 January 2024 – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of European rights to Colobreathe® from Teva Laboratories UK Limited.
  • Colobreathe® is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa (PsA) in patients with cystic fibrosis aged 6 years and older.
  • Under the terms of the acquisition, Essential Pharma has acquired the rights to Colobreathe® across European markets; the product is currently marketed across more than 20 countries in Europe, including the UK.
  • Emma Johnson, CEO of Essential Pharma, commented: “Our singular focus is on ensuring patients can maintain sustainable access to vital medicines.